4.1 Article

Measurement of nonsulfated cholecystokinins

Journal

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.3109/00365513.2014.900695

Keywords

Cholecystokinin (CCK); CCKomas; hormone biosynthesis; peptide hormones; processing-independent analysis; sequence-specific radioimmunoassay (SS-RIA); tyrosyl O-sulfation

Funding

  1. Research Foundation of Rigshospitalet (Copenhagen)
  2. Danish Biotechnology Center of Cellular Communication
  3. Lundbeck Foundation

Ask authors/readers for more resources

Most proteins undergo posttranslational modifications that govern the function of the protein. In synchrony, correspondingly unmodified proteins that are functionally silent or act differently may also be synthesized. The gut hormone precursor, procholecystokinin (proCCK) is an example of a protein that is heavily modified. An essential modification is O-sulfation of Y-77, which is necessary for the gallbladder emptying effect of CCK peptides via the CCKA-receptor. In order to examine possible in vivo synthesis also of nonsulfated CCK, we have established a two-step analysis that requires tryptic cleavage at a defined processing site in proCCK (R-75-D-76) followed by monospecific RIA-measurement of the then exposed nonsulfated N-terminal sequence of CCK-8 (DYMGW...). The analysis shows that endocrine cells in the gut synthesize nonsulfated CCK peptides (-58, -33, -22, and -8) in the order of 20 -35% of the corresponding sulfated CCKs. Since nonsulfated CCK peptides are full agonists of the CCKB -receptor, the assay has revealed a hitherto unrecognized gut hormonal peptide system. The assay may prove useful in the diagnosis and control of diseases with hyperCCKemia. This includes CCK-producing neuroendocrine tumors such as the recently described CCKomas and medullary thyroid C-cell carcinomas.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Nonsulfated cholecystokinins in the small intestine of pigs and rats

Mikkel Agersnap, Jens F. Rehfeld

PEPTIDES (2015)

Article Endocrinology & Metabolism

Nonsulfated cholecystokinins in cerebral neurons

Mikkel Agersnap, Ming-Dong Zhang, Tibor Harkany, Tomas Hokfelt, Jens F. Rehfeld

NEUROPEPTIDES (2016)

Article Gastroenterology & Hepatology

The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients

Jens F. Rehfeld, Birgitte Federspiel, Mikkel Agersnap, Ulrich Knigge, Linda Bardram

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)

Letter Gastroenterology & Hepatology

Cholecystokininoma syndrome, calcitonin and diarrhea

Jens F. Rehfeld, Birgitte Federspiel, Mikkel Agersnap, Ulrich Knigge, Linda Bardram

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2017)

Article Endocrinology & Metabolism

Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity

Christina C. Nexoe-Larsen, Pernille H. Sorensen, Helene Hausner, Mikkel Agersnap, Mille Baekdal, Andreas Bronden, Lea N. Gustafsson, David P. Sonne, Louise Vedtofte, Tina Vilsboll, Filip K. Knop

DIABETES OBESITY & METABOLISM (2018)

Review Endocrinology & Metabolism

Unsulfated cholecystokinin: An overlooked hormone?

Jens F. Rehfeld, Mikkel Agersnap

REGULATORY PEPTIDES (2012)

Article Pharmacology & Pharmacy

Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects

Mikkel Askjaer Agersnap, Kim Sonne, Kim Mark Knudsen, Carsten Boye Knudsen, Mark Berner-Hansen

Summary: This study aimed to characterize the pharmacokinetics of glepaglutide in healthy subjects. The results showed that slow release of active metabolites following subcutaneous dosing leads to a significantly protracted pharmacokinetic profile for glepaglutide. These findings support the efficacy of once- or twice-weekly subcutaneous dosing of glepaglutide for intestinal rehabilitation.

CLINICAL DRUG INVESTIGATION (2022)

Correction Pharmacology & Pharmacy

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment (Feb, 10.1007/s40262-023-01215-9, 2023)

Mikkel Askjaer Agersnap, Kim Sonne, Kim Mark Knudsen, Wladyslaw Sulowicz

CLINICAL PHARMACOKINETICS (2023)

Article Pharmacology & Pharmacy

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

Mikkel Askjaer Agersnap, Kim Sonne, Kim Mark Knudsen, Wladyslaw Sulowicz

Summary: This study explored the impact of renal function on the pharmacokinetics and safety of glepaglutide. The results showed no significant difference in the pharmacokinetics of glepaglutide between patients with renal impairment/ESRD and those with normal renal function. Therefore, dose adjustment of glepaglutide does not seem to be necessary in SBS patients with renal impairment.

CLINICAL PHARMACOKINETICS (2023)

No Data Available